ATE444077T1 - Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen - Google Patents
Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungenInfo
- Publication number
- ATE444077T1 ATE444077T1 AT01945716T AT01945716T ATE444077T1 AT E444077 T1 ATE444077 T1 AT E444077T1 AT 01945716 T AT01945716 T AT 01945716T AT 01945716 T AT01945716 T AT 01945716T AT E444077 T1 ATE444077 T1 AT E444077T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical
- diseases
- demyelination
- prevention
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 208000016192 Demyelinating disease Diseases 0.000 abstract 3
- 206010012305 Demyelination Diseases 0.000 abstract 3
- 230000001537 neural effect Effects 0.000 abstract 2
- 210000004248 oligodendroglia Anatomy 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 206010063661 Vascular encephalopathy Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000013677 cerebrovascular dementia Diseases 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000003007 myelin sheath Anatomy 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000199421 | 2000-06-30 | ||
| PCT/JP2001/005641 WO2002002135A1 (fr) | 2000-06-30 | 2001-06-29 | Preventifs et remedes contre des maladies associees a la demyelinisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444077T1 true ATE444077T1 (de) | 2009-10-15 |
Family
ID=18697441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01945716T ATE444077T1 (de) | 2000-06-30 | 2001-06-29 | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8039253B2 (de) |
| EP (1) | EP1295604B1 (de) |
| JP (1) | JP5053499B2 (de) |
| AT (1) | ATE444077T1 (de) |
| AU (1) | AU2001267882A1 (de) |
| DE (1) | DE60140054D1 (de) |
| WO (1) | WO2002002135A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820180B2 (en) | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| US8505630B2 (en) | 2005-09-09 | 2013-08-13 | Halliburton Energy Services, Inc. | Consolidating spacer fluids and methods of use |
| US8555967B2 (en) | 2005-09-09 | 2013-10-15 | Halliburton Energy Services, Inc. | Methods and systems for evaluating a boundary between a consolidating spacer fluid and a cement composition |
| US8333240B2 (en) | 2005-09-09 | 2012-12-18 | Halliburton Energy Services, Inc. | Reduced carbon footprint settable compositions for use in subterranean formations |
| US9809737B2 (en) | 2005-09-09 | 2017-11-07 | Halliburton Energy Services, Inc. | Compositions containing kiln dust and/or biowaste ash and methods of use |
| US8522873B2 (en) | 2005-09-09 | 2013-09-03 | Halliburton Energy Services, Inc. | Spacer fluids containing cement kiln dust and methods of use |
| US8505629B2 (en) | 2005-09-09 | 2013-08-13 | Halliburton Energy Services, Inc. | Foamed spacer fluids containing cement kiln dust and methods of use |
| US8609595B2 (en) | 2005-09-09 | 2013-12-17 | Halliburton Energy Services, Inc. | Methods for determining reactive index for cement kiln dust, associated compositions, and methods of use |
| US8403045B2 (en) | 2005-09-09 | 2013-03-26 | Halliburton Energy Services, Inc. | Settable compositions comprising unexpanded perlite and methods of cementing in subterranean formations |
| US9150773B2 (en) | 2005-09-09 | 2015-10-06 | Halliburton Energy Services, Inc. | Compositions comprising kiln dust and wollastonite and methods of use in subterranean formations |
| US8950486B2 (en) | 2005-09-09 | 2015-02-10 | Halliburton Energy Services, Inc. | Acid-soluble cement compositions comprising cement kiln dust and methods of use |
| US8327939B2 (en) | 2005-09-09 | 2012-12-11 | Halliburton Energy Services, Inc. | Settable compositions comprising cement kiln dust and rice husk ash and methods of use |
| US9023150B2 (en) | 2005-09-09 | 2015-05-05 | Halliburton Energy Services, Inc. | Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use |
| US8281859B2 (en) | 2005-09-09 | 2012-10-09 | Halliburton Energy Services Inc. | Methods and compositions comprising cement kiln dust having an altered particle size |
| US8307899B2 (en) | 2005-09-09 | 2012-11-13 | Halliburton Energy Services, Inc. | Methods of plugging and abandoning a well using compositions comprising cement kiln dust and pumicite |
| US9051505B2 (en) | 2005-09-09 | 2015-06-09 | Halliburton Energy Services, Inc. | Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly |
| US9676989B2 (en) | 2005-09-09 | 2017-06-13 | Halliburton Energy Services, Inc. | Sealant compositions comprising cement kiln dust and tire-rubber particles and method of use |
| US8672028B2 (en) | 2010-12-21 | 2014-03-18 | Halliburton Energy Services, Inc. | Settable compositions comprising interground perlite and hydraulic cement |
| US9006155B2 (en) | 2005-09-09 | 2015-04-14 | Halliburton Energy Services, Inc. | Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly |
| US8297357B2 (en) * | 2005-09-09 | 2012-10-30 | Halliburton Energy Services Inc. | Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use |
| DE102006004008A1 (de) * | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
| CA2661054A1 (en) | 2006-08-22 | 2008-02-28 | Chugai Seiyaku Kabushiki Kaisha | Prophylactic and/or therapeutic agents for peripheral neuropathy |
| WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| WO2010092419A1 (en) * | 2009-02-12 | 2010-08-19 | Assistance Publique - Hopitaux De Paris | Combined treatment of multiple sclerosis |
| WO2016069950A2 (en) * | 2014-10-29 | 2016-05-06 | University Of Utah Research Foundation | Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1) |
| CN115501227B (zh) * | 2021-08-02 | 2023-09-19 | 中山大学·深圳 | 化合物在制备防治脱髓鞘疾病药物的应用 |
| CN117442618B (zh) * | 2023-10-23 | 2025-11-14 | 国科大杭州高等研究院 | 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| JP3537151B2 (ja) * | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| TW586933B (en) | 1996-06-20 | 2004-05-11 | Chugai Pharmaceutical Co Ltd | Compositions for treating liver-complaints using EPO |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| KR101012932B1 (ko) | 1999-04-13 | 2011-02-08 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법 |
| US7309687B1 (en) * | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| JP2001010972A (ja) * | 1999-06-30 | 2001-01-16 | Masahiro Sakanaka | プロサポシン関連ペプチドからなる細胞保護剤 |
-
2001
- 2001-06-29 AT AT01945716T patent/ATE444077T1/de not_active IP Right Cessation
- 2001-06-29 WO PCT/JP2001/005641 patent/WO2002002135A1/ja not_active Ceased
- 2001-06-29 JP JP2002506756A patent/JP5053499B2/ja not_active Expired - Fee Related
- 2001-06-29 US US10/312,721 patent/US8039253B2/en not_active Expired - Fee Related
- 2001-06-29 AU AU2001267882A patent/AU2001267882A1/en not_active Abandoned
- 2001-06-29 DE DE60140054T patent/DE60140054D1/de not_active Expired - Lifetime
- 2001-06-29 EP EP01945716A patent/EP1295604B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5053499B2 (ja) | 2012-10-17 |
| EP1295604A4 (de) | 2005-04-27 |
| EP1295604B1 (de) | 2009-09-30 |
| US20050032682A1 (en) | 2005-02-10 |
| EP1295604A1 (de) | 2003-03-26 |
| DE60140054D1 (de) | 2009-11-12 |
| WO2002002135A1 (fr) | 2002-01-10 |
| AU2001267882A1 (en) | 2002-01-14 |
| US8039253B2 (en) | 2011-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE444077T1 (de) | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen | |
| EP0348353A3 (en) | The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases | |
| PT1040830E (pt) | Medicamento para doencas neurodegenerativas | |
| ATE230989T1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
| EP0722737A4 (de) | Arznei gegen die störung des cranialen nervan | |
| IL159299A0 (en) | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity | |
| BR0315008A (pt) | Compostos neurologicamente ativos | |
| MXPA05008649A (es) | Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios. | |
| ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
| CY1112126T1 (el) | Χρηση toy vegf 165 και των ομολογων για την αγωγη διαταραχων των νευρωνων | |
| ATE252389T1 (de) | Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| BR0009296A (pt) | Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto | |
| WO2003068147A3 (en) | Treatments for neurotoxicity in alzheimer’s disease | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| DE59304087D1 (de) | Placentaextrakt und Verfahren zu seiner Herstellung | |
| WO2023107653A3 (en) | Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement | |
| DE68901172D1 (de) | (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend. | |
| DE60004093D1 (de) | Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten | |
| ES2179166T3 (es) | Composiciones para la prevencion y tratamiento de trastornos urogenitales, que contienen bismuto y uno o mas agentes antimicrobianos. | |
| ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie | |
| WO2024108179A3 (en) | 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement | |
| GR3032531T3 (en) | Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |